About: Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in South Korea. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme (GBM), lung, and ovarian cancers; and human papilloma virus. It is also involved in the development of INV043, which is in Phase II clinical trial for the treatment of patients with prostate cancer; and in Phase I/II clinical trial to treat non-melanoma skin cancer, as well as for the treatment of oesophageal cancer. The company has collaborations with Hudson Institute of Medical Research, Peter MacCallum Cancer Centre, Dr. I&B Co., Ltd., and Hanlim Pharm Co., Ltd. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Latest price: A$0.03 (-8.11%)
IVX ASX Invion Ltd
Invion Ltd share price
Atividade de preço de IVX
Último preço
$ 0,030
Variação (24h)
-0,00 AUD (8,11%)
Volume
17.16K
Volume (média 4 sem.)
-
Abertura
$ 0,04
Variação do dia
$ 0,03 - $ 0,04
Fechamento anterior
$ 0,04
Último negócio
04 Nov, 3:35 am GMT+0
Atrasado
04 Nov, 3:35 am GMT+0
IVX price performance
Atrasado
04 Nov, 3:35 am GMT+0
IVX details
quote.marketSignals